Rhythm’s genetic obesity drug hits primary endpoint in phase 3

Phase 3 trials of Rhythm Pharmaceuticals’ setmelanotide in patients with genetic obesity have met their primary endpoints. Rhythm plans to use the data to complete a rolling submission to the FDA around the end of the year, positioning it to bring the drug to market in 2020.